<?xml version="1.0" encoding="UTF-8"?>
<ref id="B100-vaccines-08-00531">
 <label>100.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Murgia</surname>
    <given-names>M.V.</given-names>
   </name>
   <name>
    <surname>Mogler</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Certoma</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Green</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Monaghan</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Williams</surname>
    <given-names>D.T.</given-names>
   </name>
   <name>
    <surname>Rowland</surname>
    <given-names>R.R.R.</given-names>
   </name>
   <name>
    <surname>Gaudreault</surname>
    <given-names>N.N.</given-names>
   </name>
  </person-group>
  <article-title>Evaluation of an African swine fever (ASF) vaccine strategy incorporating priming with an alphavirus-expressed antigen followed by boosting with attenuated ASF virus</article-title>
  <source>Arch. Virol.</source>
  <year>2018</year>
  <volume>164</volume>
  <fpage>359</fpage>
  <lpage>370</lpage>
  <pub-id pub-id-type="doi">10.1007/s00705-018-4071-8</pub-id>
  <?supplied-pmid 30367292?>
  <pub-id pub-id-type="pmid">30367292</pub-id>
 </element-citation>
</ref>
